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Biocompatihility ofan injectable biodegradable drug delivery system for prazosin was investigated 
in Sprague-Dawley rats by histological studies after subcutaneous injection of paly (hydroxypropyl glu- 
tamate )-pmzosin (PHPG-prazosin) conjugate particles. The studies howed that (1) the acute in- 
flammatory esponse to this injectable biodegradable polymeric prodrug system was mild and of only 
short duration, (2) the chronic inflammation was minimal to zero, (3) the fibrous capsule could be 
seen starting from 7 days and became more prominent at longer time periods, (4) a collagen etwork 
was formed into the injection site after 21 days, (5) the macrophages and foreign giant cells reacted to 
the globules of conjugate particles, and (6) no adverse reactions were identified. Focal inflammation 
and the formation of the fibrous capsule around the injection site were the significant histological 
findings in the histopatholngical studies. Therefore, it is concluded that the biodegradable injectable 
PHPG-prazosin carbamate polymeric prodrug system is tissue biocompatible. 
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Introduction 
Controlled release delivery systems can be ad- 
ministered into the human body by oral, trans- 
dermal, or parenteral routes. The limitation of 
the oral routte is the relatively short duration of 
the controlled release device in the body. In con- 
trast, transdermal delivery and implantable or 
injectable delivery systems can offer long term, 
continuous delivery of drags. However, when the 
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controlled release devices are introduced by par- 
enteral routes, the body and the tissue will re- 
spond to the introduction ofthe device and cause 
local or/and systemic reaction. 
Biocompatibility is defined as "the ability of a 
material to perform with an appropriate host re- 
sponse in a specific application" [ 1 ]. To evalu- 
ate the biocompatibility of an implant, the inter- 
action between the tissue and implant as well as 
the systemic reaction to the implant should be 
investigated, In general, the studies can be con- 
ducted by in vitro and in vivo experiments. In
vitro tests usually are performed by using cell 
culture techniques and in vivo studies are car- 
ried out by implantation. The latter usually pro- 
vide a more realistic appraisal of the device. 
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As indicated by the definition of biocompati- 
bility, when a controlled release device is present 
in the tissue of the body, the interaction of the 
device and the surrounding tissue or the re- 
sponse due to the device must be acceptable or 
appropriate. For a subcutaneous implantable or 
injectable system, the evaluation of tissue re- 
sponse ~o the controlled release device is an im- 
portant criterion of the biocompatibility. The 
histological study of the implant or injection site 
can provide information about the local tissue 
environment by the observation of the interac- 
tion between tissue and the device as well as the 
resulting tissue reaction which surrounds the de- 
vice. This environment can affect he drug re- 
lease from the device and the degradation rab- 
sorption of the device. 
Studies have been conducted toinvestigate he 
biocompatibility of the polymers and their in- 
jectable or implantable controlled release deliv- 
ery systems. The investigation fthe histological 
change as a function of implant ime is the most 
commonly used method in biocompatibility 
studies of drug delivery systems. Olanoff and 
Anderson [2 ] studied the biocompatibility of the 
subcutaneous implant of tetracycline-hydroxy- 
ethyl methacrylate/methyl methacrylate copoly- 
mer drug delivery system. Since the device wasa 
trilaminate disk with a hydroxyethyl methacry- 
late-methyl methacrylate copolymer coating, the 
tissue response to the device was similar to that 
of methyl methacrylate polymer and showed no 
differences between the loaded device and the 
drug free device. The tissue reactions ofpoly(DL- 
lactide) and poly(DL-lactide-co-glyculide) mi- 
crocapsules were investigated [3,4] and it was 
concluded that non-adverse-tissue reaction oc- 
curred in response to the intramuscular injection 
of the microcapsules. Yamaguchi and Anderson 
[ 5 ] studied the bioeompatibility ofa naltrexone 
delivery system made of poly [ L-( + )-lactide-co- 
glycolide] microspheres. The only tissue change 
observed in the studies was the focal inflafama- 
tion around the mierosphere and naltrexone was 
considered to be the causative agent. Anderson 
ct al. [6,7] used a cage implant system to study 
the dynamic cellular response and enzymatic 
change at the subcutaneous implant site for 
poly (hydroxyethyl glutamine) hydrogel. The in- 
flammatory response to the poly(hydroxycthyl 
giutamine) hydrngel was observed by analyzing 
the exudate. Tissue reaction of copolymers of L- 
lcueine, L-aspartic acid, and L-aspartic acid ester 
after implantation i  the subcutaneous ti sue 
were investigated and it was found that he tissue 
reaction for the hydmphobic polymer resembled 
that of silicone rubber, whereas the relatively by. 
drophilic polymer showed more cellular eaction 
[81. 
Ideally, the result of inflammatory esponse to 
the controlled release system would be the com- 
plete recovery of the ,'~ssue. Unfortunately, this 
is rarely the case for the implantable or injecta- 
ble systems. However, the application of the 
biodegradable polymer nfret's this possibility [4 ]. 
Another aspect which should be considered inthe 
case of controlled release systems is that the 
binactive agent should release from the device 
over the desired period of time and at a desired 
rate. 
A long-term drug delivery system for prazosin 
has been prepared by covalently bound prazosin 
onto pnly(hydruxypropyl glutamate) (PHPG) 
via a carbamatc linkage [9 ]. Zero order release 
of prazosin was achieved for three weeks in in 
vitro relcase studies and in vivo studies were 
perfermed with New Zealand White rabbits. 
PHPG-prazosin carbamate conjugate particles 
were injected subcutaneously into both flanks of 
the rabbits. Following an initial burst, a nearly 
constant plasma prazosin concentration profile 
above 2 ng/ml was maintained for ! 0 days [ 9 ]. 
In this study, the histological evaluation was 
conducted inrats after subcutaneous injection of 
the biodegradable polymeric prodrug, PHPG- 
prazosin carbamate. 
Materials and methods 
Animals 
The tissue reaction studies were performed on 
male Sprague-Dawley rats. Twenty-four ats 
(~200 g) were divided into eight groups and 
each group was housed in a cage. The rats were 
kept at the University of Utah Medical Center 
Vivarium during the studies and maintained on 
food and water ad libltam. Light was controlled 
with 12 b each of day and night. 
PHPG-prazosin coxbamate conjugate 
PHPG reacted with p-nitrophenyl chlorofor- 
mate to form an active intermediate. Prazosin, 
then, was coupled onto the active intermediate 
to form a conjugate with carbamate linkage as a 
labile bond between drug and polymer [9 ]. The 
PHPG-prazosin conjugate particles (20.8_+ 5.6 
pro) were disinfected with 70% ethanol solution 
and dried under vacuum. Ten ms of conjugate 
particles were suspended in a 1 ml syringe with 
0.5 ml of saline before injection. 
Injection procedure 
Twenty-four ats were divided into eight 
groups. The injection sites on the rats were 
shaded and wiped with alcohol prep pads (70% 
isopropyl alcohol). Each rat had ! 0 mg of PHPG- 
prazosin conjugate particles (in 0.5 ml of saline ) 
injected subcutaneously into the left dorsal side 
with an 18GI needle. The control (10 mg of 
PHPG dissolved in 0.5 ml of saline) was in- 
jected subcutaneously into the right dorsal side 
of the same rat. The injection sites were marked 
by a blue marker pen and remarked every week. 
Tissue sample collection 
Three rats were killed at 1, 2, 4, 7, 14, 21, 28, 
and 60 days after injection. The injection sites 
with adjacent tissue were separated by a scalpel 
with a size of about 3 X 3 cm. The tissue samples 
were tacked by pins at the four corners on par- 
affin blocks to avoid curling and fixed in 10% 
ueutral buffered formalin solution (Sigma Di- 
agnostics, St. Louis, MO) for 3 days. The fixa- 
tive solution was replaced with fresh 10% neu- 
tral buffered formalin solution. 
Histological analysis 
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The injection sites with adjacent tissue were 
sectioned with a razor blade into 2 to 3 mm in 
thickness. The tissue sections which contained 
the injection sites were identified and dehy- 
drated with an increasing radient of ethanol 
concentration, infiltrated with xyleue, embed- 
ded in paraffin, and then sectioned. The slides 
were stained with hematoxylin and cosin so that 
the cellularity could be identified and the num- 
ber of cells counted. Masson's trichrome and Pi- 
crosirius Red were used to distinguish the fi- 
brous capsule formation and collagen deposition. 
No injection sites of the control sample were 
identified within the respective tissues. The his- 
tological evaluation was performed with light 
microscopy. Slides stained with Picrosirius Red 
stains were observed under polarized light. Fol- 
lowing evaluation of all samples, the most rep- 
resentative injection sites of the conjugate parti- 
cles for a given time and different stains were 
used to prepare 35 mm slides and photomicro- 
graphs. The slides were taken at both low (6.3 X ) 
and high (63 × ) magnification m show the gen- 
eral morphology of the injection site within the 
tissue and the cellular components during the in- 
flammatory as well as healing responses to tha 
conjugate particles. 
Results and Discussion 
In general, the tissue reaction of the injectable 
controlled release devices can be described from 
the point of view of wound healing. When the 
controlled release device is implanted or in- 
jected, the local *.issue is injured [ 10]. Initiated 
by ~,he injury, inflammation follows. Conse- 
quently, in terms of the appearance ofthe mor- 
phological changes around the devices, the in- 
flammatory reaction is usually seen in tissue 
re,;ponse to the controlled release devices [11 ]. 
The following events would ~cur  after an im- 
plantation or injection of the controlled release 
system into the body. The acute inflammation is 
the first response in a series of reactions and per- 
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Fig. 1. Subcutaneous injection sites ofPliPG-prazosln carbamate partiele~z in rats ( l day after injection ). (A) Hematoxylin and 
eosin stain (6.3X); (B) hematoxylin alto eosin stain (63×). 
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Fig. 2. Subcutaneous injection sites of PHPG-prazosin carbamate panicles in rals (2 days after injection). (A) Hematoxylin 
and cosin slain (6,3 X ); (B) hematoxylin and eosin stain (63 × ). 
186 
Fig, 3. Subculaoeous injection sites of PHPG-prazosin carbamate particles in rats (4 days after injection ), (A) Hematoxylin 
and eosin stain (6.3 X ); (B) hematoxylin and eosin stain (63×). 
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sistent inflammatory eaction leads to chronic 
inflammation [ 12 ]. 
In this study, the histological evaluation ofthe 
injection site for a period of up to 60 days was 
performed to study the biocompatibility b ob- 
servation of the inflammatory and healing re- 
sponse to PHPG-prazosin conjugate particles. 
Hematoxylin and eosin stain was used to distin- 
guish the cellular components during acute in- 
flammation, chronic inflammation, granulation, 
and fibrous encapsulation. The nuclei appeared 
as dark purple or black, whereas the cellular cy- 
toplasm and proteins were pinkish-red. Collagen 
components in samples treated with Masson's 
trichrome stain appeared blue and greenish color 
(type III collagen) or reddish-orange color (type 
I collagen) when stained with Picroshius Red 
and observed under the polarized light. The re- 
sults of the tissue response after injection of the 
conjugate particles are presented and discussed 
chronologically. 
One day: The injection site was located in the 
subdermal dipose tissue. The particles of con- 
jugate appeared collectively inc;'oid shape (Fig. 
IA). Acute inflammation, ehamctarized bypo- 
lymorphonuclear leukocytes, was noted within 
the injection site and the surrounding adipose 
tissue (Fig. IB). Focal areas of exudate were 
present within the injection site. Capillaries were 
seen in the adjacent adipose tissue. The overall 
inflammatory cell response to the conjugate par- 
ticles was considered as mild. 
Two days: Acute inflammation (polymor- 
phonuclear leukocytes) appeared to increase 
within the injection site, while the exudate de- 
creased in comparison w;,th that of I day (Fig. 
2). Capillaries and polymorphonuclear leuko- 
eytes were also found in adipose tissue surround- 
ing the injection site. 
Four days: The injection site was ,yell circum- 
scribed in an ovoid shape and the conjugate par- 
ticles were contiguous. Polymorphonuclear leu- 
kocytes and monocytes were present within the 
injection site and in the adjacent adipose tissue, 
but the number of the polymorphonuclcar leu- 
kocytes decreased in comparison with that of two 
days. Focal areas of exudate were rare within the 
injection site (Fig. 3). Capillaries were identi- 
fied in the adjacent adipose tissue. 
Seven days: The injection site remained con- 
tiguous and ovoid in shape. Inflammatory cells 
and exudate were seen in the injection site. The 
foreign body giant cells leacted to the small glob- 
ules of the conjugate particles at the margin of 
the collective particles (Fig. 4A). The acute and 
chronic inflammatory esl~,~nse in the adjacent 
adipose tissue decreased when compared to the 
previous observations. Capillaries were identi- 
fied in the adjacent adipose tissue. A thin fibrous 
capsule developed as shown in the sample stained 
with Masson's trichrome (Fig. 4B). 
Fourteen days: A developiug fibrous capsule 
surrounded and confined the ovoid shape con- 
tiguous conjugate particles in the subcutaneous 
tissue (Fig. 5A). The macrophages and foreign 
giant cells were found to react o discrete glob- 
ules of the conjugate particles within the injec- 
tion site (Fig. 5B). Both the acute and the 
chronic inflammation were minimal to zero as 
indicated by the number of polymorphonuclcar 
ieukocytes and monocytes. 
Twenty-one days: The ovoid shape injection 
site was well encapsulated by the fibrous capsule 
(Fig. 6A,B ). As seen in 14 days, within the injec- 
tion site, the macrophages and foreign giant cells 
were found to react o discrete globules of the 
conjugate particles, which was well developed 
and easy to identify (Fig. 6C). in adjacent tis- 
sue, capillaries and minimal to zero inflamma- 
tion were seen. The sample stained with £ierosi- 
rius Red showed that fibroblasts had entered the 
injection site and produced collagen (reddish- 
orange network in Fig. 6D) within the injection 
site. 
Twenty-eight days: A thicker and denser fi- 
brous capsule circumscribed the injection site 
(Fig. 7A). The macrophages and foreign giant 
ceils reacted to discrete globules of the conjugate 
particles within the whole injection site (Fig. 
7B). The network formed by collagen in the in- 
jection site can be seen in the sample treated with 
Picrosirius Red stain (Fig. 7C,D). No or mini- 
mal inflammation was noted in the adjacent 
tissue. 
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Fig. 5. Subcutaneous injection sites of PHPG-l~razosin carbamata particles in rats (14 days ~er  injection ). (A) Masson's tri- 
chrome slain (6.3 × ); (B) hematoxylin and eosin stain (63 X ,~. 
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Fig. 7. Subcutaneous injection sites of PHPG-prazosin carbamate particles in rats (28 days after injection). (A) Masson's it-i- 
chrome stain (6.3×); (B) hematoxylin and eosin slain (63X); (C) Picrosirius Red stain (6.3×); (D) Picrosirius Red stain 
(63x).  
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Sixty days: The injection sites still can be seen 
in subcutaneous ti sue in an ovoid shape. No 
acute or chronic inflammation was identified 
either in the injection site or in the adjacent tis- 
sue. Maesophages and foreign body giant cells in 
the injection site were seen reacting to discrete 
globules oftbe conjugate particles (Fig. 8A). The 
fibrous capsule was found surrounding the injec- 
tion site and small arterioles as well as capillaries 
were seen adjacent to it. Masson's triehrome and 
Pierosirius Red stains showed that flbroblasts 
had entered the injection site and a fine network 
of collagen was formed within the injection site 
(Fig. 8B). 
Focal areas cf ~eut~ inflammation were iden- 
tified for the samples at one day, two days, and 
four days. Only one ol three injection sites at each 
time period showed this microscopic focal acute 
inflammation. The other two did not show the 
injection site inflammatory esponse. The histo- 
logical finding was characterized bythe presence 
of polymorphonuelear l ukoeytes and focal areas 
of exudate. The focal inflammatory esponse was 
focal and minimal. 
In general, histologically, the acute inflamma- 
tory response to this injectable biodegradable 
polymeric prodrug system was mild and of only 
short duration (up to 7 days) and the chronic 
inflammation was minimal to zero. The fibrous 
capsule could be seen starting from 7 days and 
became more prominent at longer time periods, 
14, 21, and 28 days. A collagen etwork was de- 
veloped into the injection site after 21 days. By 
28 days, the inflammatory and healing responses 
to the conjugate were well-developed with mac- 
rophages and foreign giant cells inside the collec- 
tive conjugate particles. No adverse reactions, 
such as necrosis, degeneration, and infection, 
were identified in all samples. 
The acute inflammatory esponse to the con- 
jugate may account for the initial burst of the 
prazosin in in vivo studies hown in the previous 
publication [9], since the inflammation would 
decrease the local tissue pH [13,14]. On the 
other hand, the formation of fibrous capsule can 
be a barrier that makes the plasma levels of pra- 
195 
zosin lower than that predicted from an ideal 
model. As studied by Anderson ct al. [ 15 ], the 
drug release rate was influenced by the develop- 
ment oftbe fibrous capsule. Determination f the 
drug concentration at different distances from the 
release device surface revealed the spatial differ- 
ence of the concentration f the drug and veri- 
fied the presence of a diffusion barrier. 
Extensive tests have been performed to evalu- 
ate the biucompatibility of the norithindrone po- 
lymeric prodrug base on PHPG, PHEG, and co- 
polymer of HPO and valine [ 16,17 ]. The studies 
involved immunological nd histological tests. 
The immunological studies involved immuniza- 
tion of rabbits and guinea pigs followed by skin 
test, implantation test, agglutination test, precip- 
itation test, agar diffusion test, complement fix- 
ation test as well as passive cutaneous anaphy- 
laxis test. Histological evaluation included the 
observation of the tissue response and the ex- 
amination of the organs. All immunological tests 
were negative and tissue reactions were accepta- 
ble. Although all tests howed negative results, to 
draw a conclusion about nonimmunogenicity of 
the polymeric prodrug and polymer backbone 
still needs more rigorous and sensitive tests, for 
example, using radiotraeer technique. Dickinson 
et aL [8] studied the biodegradation f the 
poly(o~-amino acid) hydrogel by subcutaneous 
implantation and found tissue responses to the 
poly(~-amino acid) hydrogel were acute and 
chronic inflammation. 
The results of the histological studies in this 
investigation are similar to the inflammatory and 
healing response to those seen with naltrexone 
delivery system made of poly(L( + ) laetide-co- 
glycolide) mierocapsules or microbeads [5]. 
This conjugate particle system has a tissue reac- 
tion commonly seen for nondegradable or very 
slowly degradable microspheres or microcap- 
soles. It was found that the inflammatory cell 
density was higher for the naltrexone loaded 
beads than for the control, poly[I.( + ) lactide- 
co-glycolide] microcapsules or microbcads and 
was considered tobe due to released naltrexone. 
However, it was not seen in this study. 
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Conc lus ions  
In the present study the tissue response to 
PHPG-prazos in  conjugate part ic le was investi-  
gated in Sprague-Dawley rats. By studying the 
histological changes surrounding the injection 
site, the tissue compat ib i l i ty  o f  PHPG-prazos in  
conjugate was evaluated.  All inject ion sites 
showed mi ld  and short durat ion acute inf lam- 
matory response, and min imal  to no chronic in- 
f lammat ion was identif ied. The  durat ion o f  the 
acute inf lammatory response and the t ime o f  
format ion o f  the f ibrous capsule can explain the 
burst effect and the lower p lasma concentrat ion 
in in v ivo studies [9 ] .  The  signif icant histologi- 
cal f indings in this study were the local inf lam- 
mat ion and the format ion o f  the f ibrous capsule 
around the injection site. Therefore,  it  is con- 
eluded that the biodegradable injectable PHPG-  
prazosin carbamate polymeric  prodrug system is 
t issue biocompatib le.  
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